Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Insulet Announces CEO Transition
Director Jim Hollingshead to Succeed Shacey Petrovic as President and CEO, Effective June 1, 2022 Petrovic and Hollingshead to Continue as Members of Insulet’s Board of Directors ACTON, Mass. --(BUSINESS WIRE)--May 5, 2022-- Insulet Corporation (NASDAQ: PODD) ( Insulet or the Company), the global
View HTML
Toggle Summary Insulet Reports First Quarter 2022 Revenue Increase of 17% Year-Over-Year
ACTON, Mass. --(BUSINESS WIRE)--May 5, 2022-- Insulet Corporation (NASDAQ: PODD) ( Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, today announced financial results for the three months ended March 31, 2022 .
View HTML
Toggle Summary Insulet’s 2021 Sustainability Report Reveals Progress on Strategy to Deliver Growth with Purpose
ACTON, Mass. --(BUSINESS WIRE)--May 2, 2022-- Insulet Corporation (NASDAQ: PODD) ( Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, today announced the release of its 2021 Sustainability Report.
View HTML
Toggle Summary Insulet Presents New Omnipod® 5 System Data for Type 1 and Type 2 Diabetes
ACTON, Mass. --(BUSINESS WIRE)--Apr. 27, 2022-- Insulet Corporation (NASDAQ: PODD) ( Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today presented new Omnipod® 5 Automated Insulin Delivery (AID) System study results in type 2
View HTML
Toggle Summary Insulet to Announce First Quarter 2022 Financial Results on May 5, 2022
ACTON, Mass. --(BUSINESS WIRE)--Apr. 7, 2022-- Insulet Corporation (NASDAQ: PODD) ( Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, today announced plans to release its financial results for the first quarter of 2022 on May 5,
View HTML
Toggle Summary Insulet Reports Full Year 2021 Revenue Increase of 21% and Fourth Quarter 2021 Revenue Increase of 25% Year-Over-Year
Represents 6th Consecutive Year of Over 20% Revenue Growth; Annual Revenue Surpasses $1 Billion Omnipod 5 Automated Insulin Delivery System Receives U.S. FDA Clearance ACTON, Mass. --(BUSINESS WIRE)--Feb. 23, 2022-- Insulet Corporation (NASDAQ: PODD) ( Insulet or the Company), the global leader in
View HTML
Toggle Summary Insulet Promotes Inclusivity for People with Diabetes through Nintendo® Video Game Animal Crossing™: New Horizons
ACTON, Mass. --(BUSINESS WIRE)--Feb. 17, 2022-- Insulet Corporation (NASDAQ: PODD) ( Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, is celebrating representation and inclusion for the diabetes community through an activation in
View HTML
Toggle Summary Insulet to Present at Upcoming Investor Conferences
ACTON, Mass. --(BUSINESS WIRE)--Feb. 16, 2022-- Insulet Corporation (NASDAQ: PODD) ( Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, today announced that management will present at two upcoming investor conferences: The Raymond
View HTML
Toggle Summary Insulet Announces Board Appointment of Elizabeth Weatherman and Retirement of David Lemoine
ACTON, Mass. --(BUSINESS WIRE)--Feb. 7, 2022-- Insulet Corporation (NASDAQ: PODD) ( Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that Elizabeth “Bess” Weatherman has been appointed to the Company’s Board of
View HTML
Toggle Summary Insulet Announces FDA Clearance of its Omnipod® 5 Automated Insulin Delivery System, First Tubeless System with Smartphone Control
Watch Video: Omnipod® 5 is now FDA Cleared!
View HTML
Toggle Summary Insulet to Announce Fourth Quarter and Full Year 2021 Financial Results on February 23, 2022
ACTON, Mass. --(BUSINESS WIRE)--Jan. 12, 2022-- Insulet Corporation (NASDAQ: PODD) ( Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, today announced plans to release its financial results for the fourth quarter and full year of
View HTML
Toggle Summary Insulet to Present at Nasdaq’s 45th Investor Conference
ACTON, Mass. --(BUSINESS WIRE)--Nov. 24, 2021-- Insulet Corporation (NASDAQ: PODD) ( Insulet ), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, today announced that management will present at the virtual 45 th   Nasdaq Investor Conference on Friday,
View HTML
Toggle Summary Insulet Reports Third Quarter 2021 Revenue Increase of 18% Year-Over-Year
ACTON, Mass. --(BUSINESS WIRE)--Nov. 4, 2021-- Insulet Corporation (NASDAQ: PODD) ( Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, today announced financial results for the three months ended September 30, 2021 .
View HTML
Toggle Summary Insulet Honors Diabetes Awareness with Global Activities and Events
ACTON, Mass. --(BUSINESS WIRE)--Nov. 1, 2021-- Insulet Corporation (NASDAQ: PODD) ( Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, today announced various activities to recognize Diabetes Awareness Month and World Diabetes Day
View HTML
Toggle Summary Insulet Announces Board of Director Changes with Appointment of Luciana Borio, M.D. and Retirement of Sally W. Crawford
ACTON, Mass. --(BUSINESS WIRE)--Oct. 18, 2021-- Insulet Corporation (NASDAQ: PODD) ( Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that Luciana Borio , M.D., has been appointed to the Company’s Board of Directors.
View HTML